tbuckley/cabot-search huggingface dataset:
CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII
Authors: Jyoti Rana, Daniel J. Perry, Sandeep R.P. Kumar, Maite Muñoz-Melero, Rania Saboungi, Todd M. Brusko, Moanaro Biswas
Journal: Molecular Therapy (2021)

Regulatory T cells (Tregs) control immune responses in autoimmune disease, transplantation, and enable antigen-specific tolerance induction in protein-replacement therapies. Tregs can exert a broad array of suppressive functions through their T cell receptor (TCR) in a tissue-directed and antigen-specific manner. This capacity can now be harnessed for tolerance induction by "redirecting" polyclonal Tregs to overcome low inherent precursor frequencies and simultaneously augment suppressive functions. With the use of hemophilia A as a model, we sought to engineer antigen-specific Tregs to suppress antibody formation against the soluble therapeutic protein factor (F)VIII in a major histocompatibility complex (MHC)-independent fashion. Surprisingly, high-affinity chimeric antigen receptor (CAR)-Treg engagement induced a robust effector phenotype that was distinct from the activation signature observed for endogenous thymic Tregs, which resulted in the loss of suppressive activity. Targeted mutations in the CD3ζ or CD28 signaling motifs or interleukin (IL)-10 overexpression were not sufficient to restore tolerance. In contrast, complexing TCR-based signaling with single-chain variable fragment (scFv) recognition to generate TCR fusion construct (TRuC)-Tregs delivered controlled antigen-specific signaling via engagement of the entire TCR complex, thereby directing functional suppression of the FVIII-specific antibody response. These data suggest that cellular therapies employing engineered receptor Tregs will require regulation of activation thresholds to maintain optimal suppressive function.
ATTR CARDIAC AMYLOIDOSIS MEETS MULTIPLE MYELOMA: THE IMPORTANCE OF CARDIAC BIOPSY
Authors: Anthony Kanelidis, Patrick Miller, Nicole Prabhu, Mark Joshua Dela Cruz, Sara Kalantari, Francis J. Alenghat, Ivan P. Moskowitz, Nitasha Sarswat, Benjamin Derman, Tamar Polonsky, Jeanne DeCara
Journal: Journal of the American College of Cardiology (2021)
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis
Authors: Katie J Bayfield, Tonia A Douglas, Tim Rosenow, Jane C Davies, Stuart J Elborn, Marcus Mall, Anthony Paproki, Felix Ratjen, Peter D Sly, Alan R Smyth, Stephen Stick, Claire E Wainwright, Paul D Robinson
Journal: Thorax (2021)

Structural and functional defects within the lungs of children with cystic fibrosis (CF) are detectable soon after birth and progress throughout preschool years often without overt clinical signs or symptoms. By school age, most children have structural changes such as bronchiectasis or gas trapping/hypoperfusion and lung function abnormalities that persist into later life. Despite improved survival, gains in forced expiratory volume in one second (FEV 1 ) achieved across successive birth cohorts during childhood have plateaued, and rates of FEV 1 decline in adolescence and adulthood have not slowed. This suggests that interventions aimed at preventing lung disease should be targeted to mild disease and commence in early life. Spirometry-based classifications of ‘normal’ (FEV 1 ≥90% predicted) and ‘mild lung disease’ (FEV 1 70%–89% predicted) are inappropriate, given the failure of spirometry to detect significant structural or functional abnormalities shown by more sensitive imaging and lung function techniques. The state and readiness of two imaging (CT and MRI) and two functional (multiple breath washout and oscillometry) tools for the detection and monitoring of early lung disease in children and adults with CF are discussed in this article. Prospective research programmes and technological advances in these techniques mean that well-designed interventional trials in early lung disease, particularly in young children and infants, are possible. Age appropriate, randomised controlled trials are critical to determine the safety, efficacy and best use of new therapies in young children. Regulatory bodies continue to approve medications in young children based on safety data alone and extrapolation of efficacy results from older age groups. Harnessing the complementary information from structural and functional tools, with measures of inflammation and infection, will significantly advance our understanding of early CF lung disease pathophysiology and responses to therapy. Defining clinical utility for these novel techniques will require effective collaboration across multiple disciplines to address important remaining research questions. Future impact on existing management burden for patients with CF and their family must be considered, assessed and minimised. To address the possible role of these techniques in early lung disease, a meeting of international leaders and experts in the field was convened in August 2019 at the Australiasian Cystic Fibrosis Conference. The meeting entitiled ‘Shaping imaging and functional testing for early disease detection of lung disease in Cystic Fibrosis’, was attended by representatives across the range of disciplines involved in modern CF care. This document summarises the proceedings, key priorities and important research questions highlighted.
PREDICTORS OF ACUTE MYOCARDIAL INFARCTION AND ADVERSE OUTCOMES IN PATIENTS HOSPITALIZED WITH INFLUENZA
Authors: Homam Moussa Pacha, Yasar Sattar, Talha Ahmad, Abhijeet Dhoble, Konstantinos Charitakis, Salman Arain, Prakash Balan, Nils Johnson, M. Chadi Alraies, Richard Smalling, Mohammad Madjid
Journal: Journal of the American College of Cardiology (2021)
ADHERENCE TO THE 2019 FOCUSED UPDATE OF THE 2014 AHA/ACC/HRS GUIDELINE ON THE USE OF ORAL ANTICOAGULANT AGENTS IN PATIENTS WITH ATRIAL FIBRILLATION IN THE MIDDLE EAST: THE JORDAN ATRIAL FIBRILLATION STUDY
Authors: Ayman J. Hammoudeh, Nazih Kadri, Ramzi Tabbalat, Eyas Al-Mousa, Laith Habahbeh, Hesham Janabi, Yahya Badaineh, Imad Alhaddad
Journal: Journal of the American College of Cardiology (2021)
Case 13-2021: A Newborn Girl with a Neck Mass
Authors: Dorit Koren, Katherine A. Sparger, Randheer Shailam, Peter M. Sadow
Journal: New England Journal of Medicine (2021)

A newborn girl was admitted to the neonatal ICU after a planned cesarean section because of a neck mass, which was discovered on ultrasonography at 34 weeks 6 days of gestation. After birth, the mass measured 3.7 cm by 3.8 cm by 3.1 cm and displaced the internal jugular vein and carotid artery. A diagnostic procedure was performed.
Abstract 17433: Early Identification of Left Ventricular Dysfunction With Speckle Tracking Echocardiography in Antineoplastic Therapy-induced Cardiotoxicity
Authors: Carlo G Tocchetti, Carmela Coppola, Gianluca Ragone, Elisa Di Pietro, Gabriele G Schiattarella, Antonio Barbieri, Giovanni Esposito, Antonio Rapacciuolo, Nazareno Paolocci, Claudio Arra, Claudia De Lorenzo, Rosario V Iaffaioli, Nicola Maurea
Journal: Circulation (2010)

Background: New anti-ErbB2 therapies have improved the prognosis of patients with breast cancer, but are associated with an increased risk of left ventricular (LV) dysfunction. Trastuzumab (T) can ...
Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional β cells in predicting diabetes
Authors: Teresa Mezza, Pietro Manuel Ferraro, Gianfranco Di Giuseppe, Simona Moffa, Chiara M.A. Cefalo, Francesca Cinti, Flavia Impronta, Umberto Capece, Giuseppe Quero, Alfredo Pontecorvi, Andrea Mari, Sergio Alfieri, Andrea Giaccari
Journal: Journal of Clinical Investigation (2021)

BACKGROUND. The appearance of hyperglycemia is due to insulin resistance, functional deficits in the secretion of insulin, and a reduction of β cell mass. There is a long-standing debate as to the relative contribution of these factors to clinically manifesting β cell dysfunction. The aim of this study was to verify the acute effect of one of these factors, the reduction of β cell mass, on the subsequent development of hyperglycemia.
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
Authors: J. Barrière, E. Chamorey, Z. Adjtoutah, O. Castelnau, A. Mahamat, S. Marco, E. Petit, A. Leysalle, V. Raimondi, M. Carles
Journal: Annals of Oncology (2021)
COVID-19 PANDEMIC STRESS CAN TRIGGER ACUTE CARDIOVASCULAR EVENTS IN NON-INFECTED INDIVIDUALS
Authors: Ayman J. Hammoudeh, Eyadeh Madanat, Ra’ad AlMuhaisen, Ramzi Tabbalat, Hadi Abu-Hantash, Imad Alhaddad, Rashid Ibdah
Journal: Journal of the American College of Cardiology (2021)
THE EFFECT OF ASPIRATION THROMBECTOMY COMPARED TO CONVENTIONAL PCI IN PATIENTS WITH NSTEMI: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Mitra Patel, Neha Patel, Cameron Burmeister, Jeremy Tomcho, Ahmed Elzanaty, Sapan Bhuta, Sakhi Patel, Shivani Singh, Aneesha Patel
Journal: Journal of the American College of Cardiology (2021)
DIABETES HISTORY AND INCIDENT HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
Authors: Justin Echouffo Tcheugui, Sui Zhang, Roberta Florido, Carine Hamo, Jim Pankow, Erin Michos, Ronald Goldberg, Vijay Nambi, Gary Gerstenblith, Wendy Post, Roger Blumenthal, Christie Ballantyne, Josef Coresh, Elizabeth Selvin, Chiadi Ndumele
Journal: Journal of the American College of Cardiology (2021)
DIFFERENTIAL PLAQUE CHARACTER AND PROGRESSION ACCORDING TO THE LOCATION OF CORONARY ATHEROSCLEROTIC PLAQUE: PROXIMAL VERSUS OTHER LESIONS EVALUATED ON SERIAL CCTA
Authors: Maxim Bax, Yeonyee E. Yoon, Sang-Eun Lee, Ji Min Sung, Daniele Andreini, Matthew Budoff, Kavitha Chinnaiyan, Jung Hyun Choi, Eun Ju Chun, Edoardo Conte, Martin Hadamitzky, Yong-Jin Kim, Byoung Kwon Lee, Jonathon Leipsic, Erica Maffei, Pedro De Araujo Goncalves, Gianluca Pontone, Sanghoon Shin, Jagat Narula, Jeroen Bax, Fay Lin, Leslee Shaw, Hyuk-Jae Chang
Journal: Journal of the American College of Cardiology (2021)
CORONARY ORBITAL ATHERECTOMY THROUGH NEWLY DEPLOYED LEFT MAIN CORONARY STENT
Authors: Sundeep Kumar, Preetham Reddy Muskula, Ali Ghani, Hiren Patel, Ruthvik Srinivasamurthy, Akhil Mogalapalli, Elsayed Abo-Salem
Journal: Journal of the American College of Cardiology (2021)
OUTCOMES OF IDENTIFIED AND UNIDENTIFIED CARDIOGENIC SHOCK IN ST-ELEVATION MYOCARDIAL INFARCTION IN AN URBAN INNER CITY TEACHING HOSPITAL PRIOR TO SHOCK PROTOCOL IMPLEMENTATION
Authors: Shreya Ghetiya, Pujan Patel, Kerolos Fahmi, Kyeesha Becoats, Gladys Velarde, Andres Pineda Maldonado
Journal: Journal of the American College of Cardiology (2021)
PPARγ agonists promote the resolution of myelofibrosis in preclinical models
Authors: Juliette Lambert, Joseph Saliba, Carolina Calderon, Karine Sii-Felice, Mohammad Salma, Valérie Edmond, Jean-Claude Alvarez, Marc Delord, Caroline Marty, Isabelle Plo, Jean-Jacques Kiladjian, Eric Soler, William Vainchenker, Jean-Luc Villeval, Philippe Rousselot, Stéphane Prost
Journal: Journal of Clinical Investigation (2021)

Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bone marrow (BM) microenvironment. Each of these points is a potential target of PPARγ activation. Here, we demonstrated the therapeutic potential of PPARγ agonists in resolving MF in 3 mouse models. We showed that PPARγ agonists reduce myeloproliferation, modulate inflammation, and protect the BM stroma in vitro and ex vivo. Activation of PPARγ constitutes a relevant therapeutic target in MF, and our data support the possibility of using PPARγ agonists in clinical practice.
Assessment of fixed‐duration therapies for treatment‐naïve <scp>Waldenström</scp> macroglobulinemia
Authors: Jithma P. Abeykoon, Saurabh Zanwar, Stephen M. Ansell, Eli Muchtar, Rong He, Patricia T. Greipp, Rebecca L. King, Sikander Ailawadhi, Jonas Paludo, Jeremy T. Larsen, Thomas M. Habermann, David Inwards, Ronald S. Go, Gita Thanarajasingam, Francis Buadi, Angela Dispenzieri, Carrie A. Thompson, Thomas E. Witzig, Martha Lacy, Wilson Gonsalves, Grzegorz S. Nowakowski, David Dingli, Sundararajan Vincent Rajkumar, Robert A. Kyle, Taimur Sher, Vivek Roy, Allison Rosenthal, Asher A. Chanan‐Khan, Craig Reeder, Morie A. Gertz, Shaji Kumar, Prashant Kapoor
Journal: American Journal of Hematology (2021)

Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab-based frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, rituximab, cyclophosphamide (DRC); and bortezomib, dexamethasone, rituximab (BDR) in 220 treatment-naïve patients with WM, seen at Mayo Clinic between November 1, 2000 and October 31, 2019. The median follow-up was 4.5 (95%CI: 4-5) years. The R-Benda cohort (n = 83) demonstrated superior overall response rate (ORR: 98%), in comparison to DRC (n = 92, ORR: 78%) or BDR (n = 45, ORR: 84%) cohorts, p = 0.003. Similarly, longer progression-free survival (PFS) was evident with R-Benda use [median 5.2 vs. 4.3 (DRC) and 1.8 years (BDR), p < 0.001]. The time-to-next therapy (TTNT) favored R-Benda [median, not-reached, 4.4 (DRC) and 2.6 years (BDR), p < 0.001). These endpoints were comparable between the DRC and BDR cohorts. Overall survival (OS) was similar across the three cohorts, p = 0.77. In a subset analysis of 142 patients genotyped for MYD88L265P mutation, the ORR, PFS and TTNT were unaffected by the patients' MYD88 signature within each cohort. In conclusion, ORR, PFS and TTNT with R-Benda are superior compared to DRC or BDR in treatment-naïve patients with active WM. The patient outcomes with any one of these three regimens are unaffected by the MYD88L265P mutation status.
TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL
Authors: Mikhail Kosiborod, Meena Bhatta, Melanie Davies, John Deanfield, Tim Garvey, Usman Khalid, Robert Kushner, Domenica M. Rubino, Niels Zeuthen, Subodh Verma
Journal: Journal of the American College of Cardiology (2021)
REAL-WORLD ANTITHROMBOTIC TREATMENT REGIMENS IN PATIENTS UNDERGOING PERIPHERAL VASCULAR INTERVENTION: INSIGHTS FROM THE VQI REGISTRY
Authors: Megan Lee, Zain Ahmed, Jiaming Huang, Qurat-ul-ain Jelani, Edouard Aboian, MD, Poghni Peri-Okonny, Kim Smolderen
Journal: Journal of the American College of Cardiology (2021)
HYPERTENSION AND IMPAIRED LEFT VENTRICULAR SYSTOLIC FUNCTION PREDICT VENTRICULAR-ARTERIAL UNCOUPLING IN AMERICAN-STYLE FOOTBALL ATHLETES
Authors: Jason Tso, Casey Turner, Chang Liu, Syed Ahmad, Abbas Ali, Steve Selvaraj, Angelo Galante, Carla Gilson, Craig Clark, Byron Williams, Arshed Quyyumi, Aaron Baggish, Jonathan Kim
Journal: Journal of the American College of Cardiology (2021)
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?
Authors: Kinga Sałaciak, Karolina Pytka
Journal: Pharmacology & Therapeutics (2021)

Serotonin (5-HT) is one of the fundamental neurotransmitters that contribute to the information essential for an organism's normal, physiological function. Serotonin acts centrally and systemically. The 5-HT1A receptor is the most widespread serotonin receptor, and participates in many brain-related disorders, including anxiety, depression, and cognitive impairments. The 5-HT1A receptor can activate several different biochemical pathways and signals through both G protein-dependent and G protein-independent pathways. Preclinical experiments indicate that distinct signaling pathways in specific brain regions may be crucial for antidepressant-like, anxiolytic-like, and procognitive responses. Therefore, the development of new ligands that selectively target a particular signaling pathway(s) could open new possibilities for more effective and safer pharmacotherapy. This review discusses the current state of preclinical studies focusing on the concept of functional selectivity (biased agonism) regarding the 5-HT1A receptor and its role in antidepressant-like, anxiolytic-like, and procognitive regulation. Such work highlights not only the differential effects of targeted autoreceptors, vs. heteroreceptors, but also the importance of targeting specific downstream intracellular signaling processes, thereby enhancing favorable over unfavorable signaling activation.
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission
Authors: Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge C. Olsen, Hallvard Fremstad, Cristina Spada, Tor Magne Madland, Christian A. Høili, Gunnstein Bakland, Åse Lexberg, Inger Johanne Widding Hansen, Inger Myrnes Hansen, Hilde Haukeland, Maud-Kristine Aga Ljoså, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Désirée van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Journal: JAMA (2021)

<h3>Importance</h3> Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains unclear. <h3>Objective</h3> To assess the effect of tapering of csDMARDs, compared with continuing csDMARDs without tapering, on the risk of flares in patients with RA in sustained remission. <h3>Design, Setting, and Participants</h3> ARCTIC REWIND was a multicenter, randomized, parallel, open-label noninferiority study conducted in 10 Norwegian hospital-based rheumatology practices. A total of 160 patients with RA in remission for 12 months who were receiving stable csDMARD therapy were enrolled between June 2013 and June 2018, and the final visit occurred in June 2019. <h3>Interventions</h3> Patients were randomly assigned to half-dose csDMARDs (n = 80) or stable-dose csDMARDs (n = 80). <h3>Main Outcomes and Measures</h3> The primary end point was the proportion of patients with a disease flare between baseline and the 12-month follow-up, defined as a combination of Disease Activity Score (DAS) greater than 1.6 (threshold for RA remission), an increase in DAS score of 0.6 units or more, and at least 2 swollen joints. A disease flare could also be recorded if both the patient and investigator agreed that a clinically significant flare had occurred. A risk difference of 20% was defined as the noninferiority margin. <h3>Results</h3> Of 160 enrolled patients (mean [SD] age, 55.1 [11.9] years; 66% female), 156 received the allocated therapy, of which 155 without any major protocol violations were included in the primary analysis population (77 receiving half-dose and 78 receiving stable-dose csDMARDs). Flare occurred in 19 patients (25%) in the half-dose csDMARD group compared with 5 (6%) in the stable-dose csDMARD group (risk difference, 18% [95% CI, 7%-29%]). Adverse events occurred in 34 patients (44%) in the half-dose group and 42 (54%) in the stable-dose group, none leading to study discontinuation. No deaths occurred. <h3>Conclusions and Relevance</h3> Among patients with RA in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs did not demonstrate noninferiority for the percentage of patients with disease flares over 12 months, and there were significantly fewer flares in the stable-dose group. These findings do not support treatment with half-dose therapy. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01881308
SPATIAL-TEMPORAL DEEP-LEARNING FOR AUTOMATIC IDENTIFICATION OF RHEUMATIC HEART DISEASE IN ECHOCARDIOGRAPHIC SCREENING IMAGES - DATA FROM THE PROVAR-ATMOSPHERE STUDY
Authors: Bruno Ramos Nascimento, João Francisco B.S. Martins, Erickson R. Nascimento, Gisele L. Pappa, Craig Sable, Andrea Beaton, Kaciane K.B. Oliveira, Juliane Franco, Paulo R. Gomes, Domingos Sávio G. Ferreira-Filho, Augusto F.C. Pereira, Mariana D.O. Mata, Antonio Ribeiro, Wagner Meira Júnior
Journal: Journal of the American College of Cardiology (2021)
ATRIAL UPTAKE ON 99MTC-PYP SCAN IS A NOVEL IMAGING FINDING ASSOCIATED HIGHER RATES OF ATRIAL FIBRILLATION IN PATIENTS WITH OR WITHOUT ATTR CARDIAC AMYLOIDOSIS
Authors: Muzna Hussain, Ossama Abou Hassan, Trejeeve Martyn, Eoin Donnellan, Saqe Alkharabsheh, Chris Watson, Wai Hong Tang, Mazen Hanna, Deborah Kwon, Paul Cremer, Brian Griffin, Mohamed Kanj, Wael Jaber, Patrick Collier
Journal: Journal of the American College of Cardiology (2021)
THE IMPACT OF FLOW-IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT ON MORTALITY IN PATIENTS WITH LOW FLOW AND SEVERE AORTIC STENOSIS
Authors: Amer N. Kadri, George Hanzel, Ramy Mando, ahmed ali, Francis Shannon, Alessandro Vivacqua, Steven Almany, Amr Abbas
Journal: Journal of the American College of Cardiology (2021)
Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial
Authors: Jing Zhang, Jie-Ru Guo, Zan-Sheng Huang, Wan-Lei Fu, Xian-Li Wu, Na Wu, Wolfgang M. Kuebler, Felix J.F. Herth, Ye Fan
Journal: European Respiratory Journal (2021)

Background Guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as an initial investigatory technique for mediastinal nodal staging in lung cancer. However, EBUS-TBNA can be limited by the inadequacy of intact tissues, which might restrict its diagnostic yield in mediastinal lesions of certain aetiologies. We have previously shown that EBUS-guided transbronchial mediastinal cryobiopsy can provide intact samples with greater volume. Methods This randomised study determined the diagnostic yield and safety of transbronchial mediastinal cryobiopsy monitored by endosonography for the diagnosis of mediastinal lesions. Patients with a mediastinal lesion of ≥1 cm in the short axis were recruited. Following identification of the mediastinal lesion by linear EBUS, fine-needle aspiration and cryobiopsy were sequentially performed in a randomised order. Primary end-points were diagnostic yield, defined as the percentage of patients for whom mediastinal biopsy provided a definite diagnosis, and procedure-related adverse events. Results In total, 197 patients were enrolled and randomly allocated. The overall diagnostic yield was 79.9% and 91.8% for TBNA and transbronchial mediastinal cryobiopsy, respectively (p=0.001). Diagnostic yields were similar for metastatic lymphadenopathy (94.1% versus 95.6%, p=0.58), while cryobiopsy was more sensitive than TBNA in uncommon tumours (91.7% versus 25.0%, p=0.001) and benign disorders (80.9% versus 53.2%, p=0.004). No significant differences in diagnostic yield were detected between “TBNA first” and “Cryobiopsy first” groups. We observed two cases of pneumothorax and one case of pneumomediastinum. Conclusions Transbronchial cryobiopsy performed under EBUS guidance is a safe and useful approach that offers diagnostic histological samples of mediastinal lesions.
RIGHT HEART THROMBI IN ACUTE PULMONARY EMBOLISM. IS IT AN OMINOUS SIGN OR A CALL FOR THROMBOLYSIS
Authors: Justin Paul Gnanaraj, Rajesh Sekar, Nilavan Asaithambi, Siva Subramaniyam Saravanan, Venkatesan Sangareddi, Rajasekar Ramesh D, Prathap Kumar G, Tamil Selvan K, Kumaran Srinivasan, Saravana Babu S, Suriyakanth Sethupathy
Journal: Journal of the American College of Cardiology (2021)